Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2014 Feb;12(2):167-72.

Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.

Author information

1
From the Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.

Abstract

The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate. This report presents a case of a 58-year-old woman with locally advanced unresectable PDAC who was treated with sequential FOLFIRINOX for 8 cycles followed by chemoradiation, and continues to show durable disease control 18 months later. The respective roles of systemic therapy and chemoradiation for locally advanced PDAC are discussed, including optimal sequencing of these modalities, recent improvements in chemotherapy, and the question of whether radiotherapy improves survival outcomes in this disease context.

PMID:
24586078
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center